Dear Friend,

In these times of COVID-19, climate chaos and elections, independent news is more important than ever. You turn to Democracy Now! because you trust that when we're reporting on the pandemic or the uprisings against police brutality—or the climate crisis—our coverage is not brought to you by the fossil fuel, insurance or weapons industries or Big Pharma. We count on YOU to make our work possible. If everyone who visits our website gave just $8, we could cover our operating costs for 2021. Really—that’s all it would take. And today a generous supporter will double your donation to Democracy Now!, meaning your gift will go twice as far. This is a challenging time for us all, but if you're able to make a donation, please do so today. Stay safe, wear a mask and thank you so much.
-Amy Goodman

Non-commercial news needs your support.

We rely on contributions from you, our viewers and listeners to do our work. If you visit us daily or weekly or even just once a month, now is a great time to make your monthly contribution.

Please do your part today.


Pfizer to Seek Emergency Authorization of COVID-19 Vaccine, Touting 95% Efficacy

HeadlineNov 19, 2020

The drugmaker Pfizer said Wednesday it will seek emergency use authorization for its coronavirus vaccine, after it proved 95% effective at preventing COVID-19 in a large clinical trial. Pfizer also reports the vaccine poses no serious safety concerns and appears to prevent severe disease among those recipients who become infected with the coronavirus. The findings have not yet been peer-reviewed, and the vaccine still has to be reviewed by the Food and Drug Administration. It’s not known how long recipients of Pfizer’s vaccine will remain protected against COVID-19 or whether the vaccine confers “sterilizing immunity” that would prevent vaccinated people from passing infections along to other people. 

The original content of this program is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License. Please attribute legal copies of this work to Some of the work(s) that this program incorporates, however, may be separately licensed. For further information or additional permissions, contact us.

Non-commercial news needs your support

We rely on contributions from our viewers and listeners to do our work.
Please do your part today.
Make a donation